vs

Side-by-side financial comparison of International Money Express, Inc. (IMXI) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

International Money Express, Inc. is the larger business by last-quarter revenue ($147.4M vs $75.5M, roughly 2.0× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -10.5%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $-20.0M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs -1.0%).

American Express Company or Amex is an American bank holding company and multinational financial services corporation that specializes in payment cards. It is headquartered at 200 Vesey Street, also known as American Express Tower, in the Battery Park City neighborhood of Lower Manhattan.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

IMXI vs PBYI — Head-to-Head

Bigger by revenue
IMXI
IMXI
2.0× larger
IMXI
$147.4M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+38.2% gap
PBYI
27.7%
-10.5%
IMXI
More free cash flow
PBYI
PBYI
$34.4M more FCF
PBYI
$14.4M
$-20.0M
IMXI
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
-1.0%
IMXI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IMXI
IMXI
PBYI
PBYI
Revenue
$147.4M
$75.5M
Net Profit
$8.9M
Gross Margin
69.3%
Operating Margin
7.9%
22.7%
Net Margin
6.1%
Revenue YoY
-10.5%
27.7%
Net Profit YoY
-41.9%
EPS (diluted)
$0.29
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMXI
IMXI
PBYI
PBYI
Q4 25
$147.4M
$75.5M
Q3 25
$154.9M
$54.5M
Q2 25
$161.1M
$52.4M
Q1 25
$144.3M
$46.0M
Q4 24
$164.8M
$59.1M
Q3 24
$171.9M
$80.5M
Q2 24
$171.5M
$47.1M
Q1 24
$150.4M
$43.8M
Net Profit
IMXI
IMXI
PBYI
PBYI
Q4 25
$8.9M
Q3 25
$5.0M
$8.8M
Q2 25
$11.0M
$5.9M
Q1 25
$7.8M
$3.0M
Q4 24
$15.4M
Q3 24
$17.3M
$20.3M
Q2 24
$14.0M
$-4.5M
Q1 24
$12.1M
$-4.8M
Gross Margin
IMXI
IMXI
PBYI
PBYI
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Q1 24
75.5%
Operating Margin
IMXI
IMXI
PBYI
PBYI
Q4 25
7.9%
22.7%
Q3 25
6.8%
17.6%
Q2 25
12.1%
12.7%
Q1 25
9.8%
8.7%
Q4 24
15.0%
22.6%
Q3 24
16.2%
27.4%
Q2 24
13.4%
-4.6%
Q1 24
13.0%
-5.3%
Net Margin
IMXI
IMXI
PBYI
PBYI
Q4 25
6.1%
Q3 25
3.2%
16.2%
Q2 25
6.8%
11.2%
Q1 25
5.4%
6.5%
Q4 24
9.3%
Q3 24
10.1%
25.2%
Q2 24
8.2%
-9.6%
Q1 24
8.0%
-11.0%
EPS (diluted)
IMXI
IMXI
PBYI
PBYI
Q4 25
$0.29
$0.26
Q3 25
$0.17
$0.17
Q2 25
$0.37
$0.12
Q1 25
$0.25
$0.06
Q4 24
$0.49
$0.40
Q3 24
$0.53
$0.41
Q2 24
$0.42
$-0.09
Q1 24
$0.35
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMXI
IMXI
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$168.7M
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$161.1M
$130.3M
Total Assets
$517.7M
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMXI
IMXI
PBYI
PBYI
Q4 25
$168.7M
$97.5M
Q3 25
$94.4M
Q2 25
$96.0M
Q1 25
$93.2M
Q4 24
$130.5M
$101.0M
Q3 24
$96.7M
Q2 24
$96.8M
Q1 24
$107.2M
Total Debt
IMXI
IMXI
PBYI
PBYI
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
IMXI
IMXI
PBYI
PBYI
Q4 25
$161.1M
$130.3M
Q3 25
$149.7M
$115.3M
Q2 25
$142.3M
$104.7M
Q1 25
$139.2M
$97.1M
Q4 24
$134.9M
$92.1M
Q3 24
$141.8M
$71.1M
Q2 24
$142.4M
$48.5M
Q1 24
$138.2M
$51.0M
Total Assets
IMXI
IMXI
PBYI
PBYI
Q4 25
$517.7M
$216.3M
Q3 25
$478.7M
$202.9M
Q2 25
$518.0M
$194.9M
Q1 25
$490.6M
$196.2M
Q4 24
$462.4M
$213.3M
Q3 24
$480.9M
$220.7M
Q2 24
$612.4M
$205.0M
Q1 24
$548.7M
$214.1M
Debt / Equity
IMXI
IMXI
PBYI
PBYI
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMXI
IMXI
PBYI
PBYI
Operating Cash FlowLast quarter
$-15.6M
$14.4M
Free Cash FlowOCF − Capex
$-20.0M
$14.4M
FCF MarginFCF / Revenue
-13.6%
19.1%
Capex IntensityCapex / Revenue
3.0%
0.0%
Cash ConversionOCF / Net Profit
-1.75×
TTM Free Cash FlowTrailing 4 quarters
$15.8M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMXI
IMXI
PBYI
PBYI
Q4 25
$-15.6M
$14.4M
Q3 25
$-28.7M
$9.7M
Q2 25
$39.9M
$14.1M
Q1 25
$41.3M
$3.6M
Q4 24
$-4.9M
$15.6M
Q3 24
$29.3M
$11.0M
Q2 24
$-19.6M
$1.0M
Q1 24
$48.2M
$11.2M
Free Cash Flow
IMXI
IMXI
PBYI
PBYI
Q4 25
$-20.0M
$14.4M
Q3 25
$-35.5M
$9.7M
Q2 25
$35.3M
$14.1M
Q1 25
$36.0M
$3.6M
Q4 24
$-8.8M
$15.6M
Q3 24
$23.4M
$11.0M
Q2 24
$-26.2M
$1.0M
Q1 24
$34.8M
FCF Margin
IMXI
IMXI
PBYI
PBYI
Q4 25
-13.6%
19.1%
Q3 25
-22.9%
17.7%
Q2 25
21.9%
26.8%
Q1 25
25.0%
7.7%
Q4 24
-5.4%
26.4%
Q3 24
13.6%
13.7%
Q2 24
-15.3%
2.1%
Q1 24
23.1%
Capex Intensity
IMXI
IMXI
PBYI
PBYI
Q4 25
3.0%
0.0%
Q3 25
4.4%
0.0%
Q2 25
2.8%
0.0%
Q1 25
3.7%
0.1%
Q4 24
2.4%
0.0%
Q3 24
3.4%
0.0%
Q2 24
3.9%
0.0%
Q1 24
9.0%
0.0%
Cash Conversion
IMXI
IMXI
PBYI
PBYI
Q4 25
-1.75×
Q3 25
-5.78×
1.10×
Q2 25
3.63×
2.41×
Q1 25
5.31×
1.21×
Q4 24
-0.32×
Q3 24
1.69×
0.54×
Q2 24
-1.39×
Q1 24
3.98×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IMXI
IMXI

Wire Transfer And Money Order$121.2M82%
Other$21.0M14%
Financial Service Other$5.2M4%

PBYI
PBYI

Segment breakdown not available.

Related Comparisons